About us
Team
Supervisory Board
Scientific Advisory Board
Technology
Pipeline
Investors
Career
News & Events
Contact us
Menu
About us
Team
Supervisory Board
Scientific Advisory Board
Technology
Pipeline
Investors
Career
News & Events
Contact us
About us
Team
Supervisory Board
Scientific Advisory Board
Technology
Pipeline
Investors
Career
News & Events
Contact us
About us
Team
Supervisory Board
Scientific Advisory Board
Technology
Pipeline
Investors
Career
News & Events
Contact us
Imprint
Privacy Statement
Disclaimer
Imprint
Privacy Statement
Disclaimer
News & Events
News
Our latest Press Releases
Fierce Biotech Names Tubulis a “Fierce 15” Biotech Company of 2024
August 5, 2024
Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer
June 27, 2024
Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma
June 20, 2024
More News
EVENTS
Meet Tubulis live
Participation
Morgan Stanley 22nd Annual Global Healthcare Conference, NYC
September 4 – 6, 2024
Presentation
ADC Pharma & Biotech Partnering Summit, Boston
September 9-10, 2024
Event
ESMO Congress
September 13 – 17, 2024
Poster
Ovarian Cancer Research Symposium, Seattle
September 20-21, 2024
Presentation
Festival of Biologics, Basel
October 15-17, 2024
Participation
Jefferies London Healthcare Conference
November 19-21, 2024
More Events
